About Pharos iBio
The Best Target & The Best Chemical
Pharos iBio is a new drug development company that develops treatments for rare and refractory diseases using a new drug development platform based on big data and AI technology.

- Based on big data analysis and artificial intelligence (AI) technology using BT&IT technology, we developed and built Chemiverse Platform, a new drug development platform, to introduce innovative new drug candidates.
- Development of new drugs specializing in rare and refractory diseases treatment and expansion of pipelines based on proprietary technology and innovative platform
- Expanding human and material resources and pursuing challenges beyond the limits through open innovation strategies
- Pharos iBio Information
-
Company
NamePharos iBio Co., Ltd.
-
Date of
EstablishmentApr 19, 2016
-
Business Area
Big data and AI-based new drug development system Development of new drug specializing in treatment of rare and refractory diseases
-
Head office
1407&1408, 38, Heungan-daero 427beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, Republic of Korea
-
Overseas
SubsidiaryUSA, Australia
-
Number of
Employees32 workers
(R&D manpower : 26, 81%)
* As of May 18, 2023 -
Open innovation
Yonsei University College of medicine SBSI
Graduate School of New Drug Discovery and Development, CNU
Seoul National University
Kangwon National University
Hannam University
C&R Research
A number of other basic R&D specialized institutions